FEB 15, 2018 12:59 PM PST

Cancer-Killing Virus Collaborates with the Human Immune System

WRITTEN BY: Kara Marker

An unlikely collaboration between a virus and the human immune system is working to address a common enemy: cancer. From the University of California San Francisco (UCSF), researchers are working with biotech professionals to understand why it’s possible to create cancer vaccines out of viruses that kill tumors and activate the immune system.

High magnification micrograph of a acinar cell carcinoma of the pancreas. Credit: Wikimedia user Nephron

Scientists first noticed the relationship between viral infections and cancer depletion a century ago, yet the first oncolytic viral therapy to be approved by the FDA was only in 2015. Now, scientists want to understand more about how viruses in cancer vaccines work to both kill cancer cells and activate the immune system against cancer. Additionally, there could be ways to combine the cancer vaccine approach with existing cancer immunotherapy drugs.

UCSF researchers collaborated with experts from SillaJen Biotherapeutics Inc. SillaJen is developing an oncolytic viral therapy called Pexa-Vec for use in primary liver and colorectal cancers. It is based on a virus engineered from the harmless vaccinia cowpox virus, the key ingredient of the very first vaccine, the vaccine to prevent smallpox. In the context of Pexa-Vec, the virus attacks cancer by cutting off the tumor supply to blood vessels.

“This virus could be given systemically by intravenous injection, in contrast to most oncolytic viruses that are injected into the tumor itself, which obviously limits their therapeutic potential against cancers that are inaccessible or have spread to multiple sites in the body," explained UCSF’s Donald McDonald, MD, PhD.

Using an animal model of neuroendocrine pancreatic cancer, researchers injected Pexa-Vec into mice to identify the ways the virus worked to kill cancer cells and if there were opportunities to improve it.

They saw that the virus did not infect healthy organs or cause illness, but it did infect blood vessels in tumors. This infection exposed tumor proteins to both the virus and the immune system, activating CD8+ T cells, also known as cytotoxic T cells.

The virus directly killed some tumor cells (five percent), but the majority of the tumor destruction was directed by the immune system five days after injection.

"The question with immunotherapy has always been - why doesn't the immune system naturally detect and attack cancer cells?" McDonald said. "It seems like these viruses are like setting off a bomb that jars the immune system. The infection releases tumor antigens in a way that jump-starts the immune response."

Next, the researchers tested the impact of combining the cancer vaccine with an additional immunotherapy drug called sunitinib, which inhibits blood vessel growth in tumors and influences the immune system. Together with the cancer vaccine, sunitinib greatly enhanced the number of tumor cells killed. The drug does this indirectly, researchers found, by boosting the activation of the immune system in response to tumor proteins exposed by the cancer vaccine virus.

“Pexa-Vec is working like a vaccine to sensitize the immune system to attack cancer," said James Burke, CMO of SillaJen Biotherapeutics. “If the virus is igniting a fire within the tumor, we want to see if we can use these immune modulators to pour gas on the flames."

The present study was published in the journal Cancer Research.

Source: University of California San Francisco

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 17, 2020
Immunology
FEB 17, 2020
Another HIV vaccine attempt fizzles out
Years of work and over $100 million in study costs have been abandoned after an HIV-vaccine tested in South Africa faile ...
FEB 21, 2020
Drug Discovery & Development
FEB 21, 2020
New Antibiotics Found Using AI Technology
Using AI, researchers at MIT have found a powerful new antibiotic capable of killing some of the most dangerous drug-res ...
APR 15, 2020
Immunology
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
APR 21, 2020
Immunology
APR 21, 2020
Sino Biological Focuses on Serological Studies of COVID-19
April 17, 2020, Sino Biological announced this week that the company launched the world’s first coronavirus antige ...
MAY 17, 2020
Genetics & Genomics
MAY 17, 2020
How Non-Coding Genomic Regions Influence Autoimmune Disease
Scientists have gained new insight into autoimmune and allergic disorders.
MAY 26, 2020
Drug Discovery & Development
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
Loading Comments...